Clinical trials: Atopic
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis
This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT03747575
- Testing
- MSTT1041A
- Where
- 21 sites in United States, Germany and 1 more
- Volunteers
- 65 people
- Sponsor
- Genentech, Inc.
Dermatitis, Atopic
Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
B7451013 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Trial name
- JADE Mono-2 (NCT03575871)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 115 sites in United States, Australia and 11 more
- Volunteers
- 391 people
- Sponsor
- Pfizer
Atopic Dermatitis
Prospective, Randomized, Double Blind Comparative Study on the Use of Two Creams in Xerosis Atopic Probands
Atopic dermatitis (AD), a chronic and relapsing inflammatory skin disease, is associated with elevated IgE levels and Th2 responses.
- Trial name
- NCT00509535
- Testing
- vitreoscilla filiformis cream
- Where
- Germany
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- L'Oreal
Atopic Dermatitis
HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
This study is a randomized, double-blind, placebo-controlled, multicenter Phase Ib/II clinical study designed to evaluate the efficacy, safety, and PK characteristics of HL-300 ointment with different concentration regimens for…
- Trial name
- NCT07629778
- Testing
- HL-300
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Dermatitis, Atopic
A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis
The main purpose of this study is to investigate the safety, tolerability, and efficacy of the study drug known as LY3454738 in healthy participants and participants with atopic dermatitis. The study has three parts.
- Trial name
- NCT03750643
- Testing
- LY3454738
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis (AD)
A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis
To investigate the superiority of 1% OPA-15406 foam to the vehicle in adult patients with atopic dermatitis (AD).
- Trial name
- NCT07173478
- Testing
- OPA-15406, Vehicle
- Where
- Japan
- Volunteers
- 156 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis
Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream
The principle aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 39652 cream is administered cutaneously as single dose to subjects with atopic dermatitis and to healthy subjects.
- Trial name
- NCT01850849
- Testing
- LEO 39652 cream, cream vehicle
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Atopic Dermatitis
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 4-arm study in adult participants with moderate to severe AD who are inadequately controlled with topical therapies or for whom such…
- Trial name
- ADVANTA (NCT06058156)
- Testing
- SAR444656 (KT-474)
- Where
- 37 sites in United States, Czechia and 4 more
- Volunteers
- 70 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis
This was a randomized, double-blind, placebo-controlled, parallel-group study to assess safety and efficacy of ZPL389 in subjects with moderate to severe atopic dermatitis with a total study duration up to 24 weeks
- Trial name
- NCT03517566
- Testing
- ZPL389 3mg, ZPL389 10mg, ZPL389 30mg
- Where
- 89 sites in United States, Austria and 14 more
- Volunteers
- 293 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis (AD)
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT07298395
- Testing
- ENV-294
- Where
- 32 sites in United States
- Volunteers
- 105 people
- Sponsor
- Enveda Therapeutics
Treatment-resistant Pruritus Associated With Atopic Dermatitis
Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
This is randomized, double-blind, placebo-controlled study to test whether VLY-686 can reduce chronic pruritus in subjects with treatment-resistant pruritus associated with atopic dermatitis in comparison with placebo.
- Trial name
- NCT02004041
- Testing
- VLY-686
- Where
- 5 sites in Germany
- Volunteers
- 69 people
- Sponsor
- Vanda Pharmaceuticals
Dermatitis, Atopic
Investigation of Topical SB705498 on Healthy Volunteers
A two part, randomized, double-blind, placebo controlled study to investigate the effects of topical doses of SB705498 in healthy volunteers.
- Trial name
- NCT01673529
- Testing
- SB705498
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
The purpose of this research study is to determine whether the study drug, EDP1815, is safe and effective in the treatment of atopic dermatitis compared with placebo.
- Trial name
- NCT05121480
- Testing
- EDP1815
- Where
- 59 sites in United States, Australia and 4 more
- Volunteers
- 421 people
- Sponsor
- Evelo Biosciences, Inc.
Mild to Moderate Atopic Dermatitis
Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.
Elidel® is indicated for the short-term treatment and long-term management of signs and symptoms of atopic dermatitis (AD) in infants (3 to 23 months), children (2 to 11 years), adolescents (12 to 17 years), and adults.
- Trial name
- Elidel-SEA (NCT06052995)
- Testing
- Elidel 1% Topical Cream
- Where
- 9 sites in Malaysia, Taiwan and 1 more
- Volunteers
- 130 people
- Sponsor
- BGP Products Operations GmbH, a Viatris company
Atopic Dermatitis, Eczema
Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)
Nanocrystalline silver (very small particles of silver) is the active ingredient in Acticoat dressings, which have been approved for the treatment of burns and other wounds.
- Trial name
- NCT00076375
- Testing
- Nanocrystalline silver cream (NPI)
- Where
- 19 sites in United States
- Volunteers
- 180 people
- Sponsor
- Nucryst Pharmaceuticals
Dermatitis Atopic
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe atopic dermatitis (AD) with a history of…
- Trial name
- SHORE (NCT06224348)
- Testing
- Amlitelimab, Topical corticosteroids, Topical calcineurin inhibitors
- Where
- 167 sites in United States, Argentina and 12 more
- Volunteers
- 643 people
- Sponsor
- Sanofi
Atopic Dermatitis
Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis
The aim of the trial is to assess Adrenal Suppression potential when pediatric subjects are administered Product 0405 for the treatment of Atopic Dermatitis
- Trial name
- 0405-01-04 (NCT01232543)
- Testing
- Product 0405
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Atopic Asthma
Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic Subjects
The purpose of this study is to determine the accuracy of the Novel point of care test (POCT) total IgE assay in atopic patients. 120 patients with atopic conditions and approximately 40 healthy subjects will be enrolled.
- Trial name
- NCT02758548
- Testing
- Blood sample, POCT device
- Where
- 12 sites in Germany, Italy and 3 more
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Impact of the Daily Use of Emollient on Corticosteroids Consumption in Patients With Atopic Dermatitis
This study aims at assessing the reduction of consumption of corticosteroids (same mid-potent corticosteroids for all patients) afforded by the use of a specific emollient in comparison to the usual one in subjects suffering from…
- Trial name
- NCT05644691
- Testing
- Lipikar Baume AP+M, Usual emollient
- Where
- Slovakia
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Atopic Dermatitis
Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.
The purpose of this study is to determine whether QAW039 is safe and has beneficial effects in people who have moderate to severe atopic dermatitis (AD).
- Trial name
- NCT01785602
- Testing
- QAW039
- Where
- 18 sites in Australia, Austria and 6 more
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals